Dicerna Pharmaceuticals, Inc.
(NASDAQ GS: DRNA)
Rigrodsky Law, P.A. is investigating Dicerna Pharmaceuticals, Inc. (“Dicerna”) regarding possible breaches of fiduciary duties and other violations of law related to Dicerna’s agreement to be acquired by Novo Nordisk A/S. Under the terms of the agreement, Dicerna’s shareholders will receive $38.25 in cash for each share of Dicerna common stock they own.